Recent data suggest that Pancreatic Neuroendocrine Tumours (PanNETs) originate from α- or β-cells of the islets of Langerhans. The majority of PanNETs are non-functional and do not express cell-type specific hormones. In the current study we examine whether tumour DNA methylation (DNAme) profiling combined with genomic data is able to identify cell of origin and to reveal pathways involved in PanNET progression. We analyse genome-wide DNAme data of 125 PanNETs and sorted α- and β-cells. To confirm cell identity, we investigate ARX and PDX1 expression. Based on epigenetic similarities, PanNETs cluster in α-like, β-like and intermediate tumours. The epigenetic similarity to α-cells progressively decreases in the intermediate tumours, which present unclear differentiation. Specific transcription factor methylation and expression vary in the respective α/β-tumour groups. Depending on DNAme similarity to α/β-cells, PanNETs have different mutational spectra, stage of the disease and prognosis, indicating potential means of PanNET progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721725 | PMC |
| http://dx.doi.org/10.1038/s42003-020-01479-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Indoleamine-2,3-dioxygenase (IDO) converts L-tryptophan (T) to L-kynurenine (K) resulting in an immunosuppressive microenvironment. Aim of the current study is to evaluate in patients with neuroendocrine tumor (NET): 1) T and K concentrations; 2) correlation with clinical outcome; 3) relationship between IDO activity and inflammatory cytokines.
Methods: A cross-sectional study was performed to investigate the IDO pathway in patients in follow-up for NET.
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Insulinoma; a diagnostic challenge: a case report.
J Pak Med Assoc
January 2025
Department of Endocrinology, Shaukat Khanum Cancer Memorial Hospital and Research Centre, Lahore, Pakistan.
Insulinoma is a pancreatic neuroendocrine tumour that primarily leads to episodes of hypoglycaemia due to inappropriate and excessive secretion of insulin. It classically presents with neuroglycopenic and autonomic sympathetic symptoms, which resolve promptly with glucose administration. Elevated level of insulin and Cpeptide in the presence of low plasma glucose level and absence of plasma sulfonylurea are diagnostic features.
View Article and Find Full Text PDFIncidence and risk factors for insulinoma diagnosed in dogs under primary veterinary care in the UK.
Sci Rep
January 2025
Department of Clinical Science and Services, Royal Veterinary College, Hatfield, AL9 7TA, UK.
Insulinoma is the most common pancreatic tumor diagnosed in dogs. This study aimed to report incidence risk, breed predispositions and other demographic risk factors for insulinoma diagnosed in dogs under primary veterinary care in the UK. The VetCompass Program supports research on anonymized electronic health records (EHRs) from dogs under UK veterinary care.
View Article and Find Full Text PDFIdeal outcome after pancreatic resection for neuroendocrine tumors: a nationwide study.
HPB (Oxford)
January 2025
Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands; Amsterdam Center for Endocrine and Neuroendocrine Tumors (ACcENT), Amsterdam, the Netherlands. Electronic address:
Background: Pancreatic resections for pancreatic neuroendocrine tumors (pNET) may experience a higher complication rate than for pancreatic ductal adenocarcinoma (PDAC). This study aimed to determine the rate of the novel composite "Ideal Outcome" measure after resection for pNET, using PDAC as reference.
Methods: This observational cohort study included all consecutive patients after pancreatic resection for pNET and PDAC using the nationwide Dutch Pancreatic Cancer Audit (2014-2021).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!